With AD, 36 million individuals are estimated to be affected in 2010 growing to 115 million by 2050 [2]. And AD caregivers in a 2 to 1 ratio add an additional 200 million or so individuals indirectly affected by the disease. These are staggering numbers by any measure — but especially for two diseases with few, if any, effective treatments despite major investments by biopharma over the past tw...